Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stair-climbing wheelchairs

This article was originally published in The Gray Sheet

Executive Summary

Petition seeking the reclassification of the devices (21 CFR 890.3890) from Class III to Class II is submitted to FDA on Sept. 2 by the Washington, D.C. law firm of Barnes, Richardson & Colburn on behalf of Garaventa Ltd. The petition cites as justification the development of published standards since FDA initially classified stair-climbing wheelchairs. With the request, FDA must consult with an advisory panel and publish a notice denying the request or announcing its intent to initiate a proceeding to reclassify the devices within 60 days of its Aug. 18 call for premarket approval applications or product development protocols ("The Gray Sheet" Aug. 24, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010659

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel